Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.

The Lancet. Respiratory medicine - 1 Dec 2014

Rosell Rafael, Karachaliou Niki, Wolf Juergen, Ou Sai-Hong Ignatius

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Clinical Trials as Topic
Share to Drug Resistance, Neoplasm
Share to Gene Rearrangement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 25466349
DOI: 10.1016/S2213-2600(14)70259-0

Genes

ALK
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.PMID 25466349Read ↗

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).Semantic proximity Read ↗

Molecular Targets Beyond the Big 3.Semantic proximity Read ↗

ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancerSemantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to DateSemantic proximity Read ↗

RET, ROS1 and ALK fusions in lung cancerSemantic proximity Read ↗

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancerSemantic proximity Read ↗

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistanceSemantic proximity Read ↗

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.Semantic proximity Read ↗

Current Landscape of Targeted Therapy in Lung Cancer.Semantic proximity Read ↗

Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward.Semantic proximity Read ↗

Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.